

# Risk Factors Predicting Chemotherapy-induced Severe Neutropenia and Outcome in Advanced Stage Non-small Cell Lung Cancer: Data from the Limited Resource in Thailand

Sunee Neesanun

Medical Oncology Unit, Department of Medicine,  
Sawanpracharak Hospital, Thailand.

**Introduction:** Chemotherapy-induced severe neutropenia requires dose reduction, delay in treatment, or discontinuation, and induces neutropenic complications resulting in poor outcomes and increased healthcare costs. This study aims to identify the risk factors for chemotherapy-induced severe neutropenia and outcome in advanced-stage NSCLC.

**Method:** From July 2014-January 2019, advanced-stage NSCLC who received chemotherapy were retrospectively analyzed. Demographic and risk factors data were collected from the electronic medical record system. Univariate and multivariate logistic regression analyses were performed to identify risk factors for severe neutropenia. Survival curves were estimated using the Kaplan-Meier method.

**Results:** Among 259 patients, 37 (14.28%) and 3 patients (1.2%) developed severe neutropenia and febrile neutropenia respectively. In multivariate analysis, restriction of protein diet (OR 9.54; 95%CI 2.44-37.24; P=0.001), concomitant use herbal medicine (OR 8.66; 95% CI 1.04-72.07; P=0.045), high BMI (OR3.1; 95% CI 1.07-8.99; P=0.04), renal disease (OR 3.9; 95% CI 1.7-8.91; P=0.001), number of cycle chemotherapy > 4 (OR 3.97; 95% CI 1.11-14.18; P=0.03) were significant predictors of Chemotherapy-induced severe neutropenia. No difference in response rate, progression-free survival and overall survival among groups (RR 18.9% vs 26.7%; median PFS; 9.6 vs 8.2 months, P=0.32 and median OS 13.8 vs 16.7 months, P=0.79 in severe and non-severe neutropenia respectively).

**Conclusions:** The present study indicates that protein-restricted diet, concomitant use of herbal medicine, BMI  $\geq 25$  kg/m<sup>2</sup>, renal disease, and more than 4 cycles of chemotherapy are significant risk factors for chemotherapy-induced severe neutropenia. Therefore, patients with these risk factors should be more carefully monitored.

---

## Introduction

Lung cancer is the second most common cancer worldwide, with an estimated 2.2 million new cases and 1.2 million deaths of lung cancer in 2020 [1]. Approximately 85% of all lung cancer patients have Non- Small Cell Lung Cancer (NSCLC) and are often diagnosed with advanced-stage cancer [2]. Nowadays, there are many treatment options for advanced-stage NSCLC such as chemotherapy, targeted therapy or immunotherapy [3- 5]. However, chemotherapy is a backbone treatment for non-targetable mutations or doesn't access novel treatment NSCLC on the basis of improvement in survival and quality of life [5-8].

Chemotherapy—although an effective treatment for lung cancer—has multiple side effects including neutropenia, a serious hematologic toxicity; it requires dose reduction, delay in treatment or discontinuation resulting in poor oncologic outcomes [9, 10]. Moreover, severe neutropenia often induces neutropenic complications or fatal infection and requires antibiotics or hospitalization; this increases healthcare costs [9, 11, 12]. Therefore, it is important to recognize the risk factors for

chemotherapy- induced severe neutropenia (CISN) in advanced-stage NSCLC. In previous studies, general risk factors for CISN includes elderly age, poor Eastern Cooperative Oncology

Group (ECOG) performance, advanced-stage disease, hematologic malignancy, low baseline WBC, neutrophil count, hemoglobin, serum albumin, multiple comorbid diseases [13-20]. However, data largely comes from literature in breast cancer and hematologic malignancy, with multiple compound treatments. The predictive factors of CISN specifically in NSCLC patients treated with limited resources remain lack of information. Therefore, the purpose of this study is to find NSCLC-specific predictive factors and implications for patient’s response rate and survival.

## Materials and Methods

Patients were eligible for inclusion in the study if they were 18 years of age or older, had histological/cytological confirmation for new case or recurrence of stage IIIB-IV NSCLC who received at least one cycle of chemotherapy, and one toxicity case report from the medical oncology unit at Sawanpracharak hospital, Thailand.

Data collection and assessment. All data were collected from the electronic medical record. The information was evaluated regarding age, sex, body weight, Body Mass Index (BMI), smoking history, ECOG, histology, stage, organ metastasis, comorbid disease, concomitant medications, blood cell count, serum albumin, serum creatinine, details of prior treatment, regimen chemotherapy, number of cycles chemotherapy and side effects. All patients were assessed by history taking, physical examination, and laboratory testing assessment (blood count and chemistry report) before each cycle of chemotherapy administrated. The chemotherapy regimen was selected depend on oncologist.

The severity of adverse events is classified according to the Common Toxicity Criteria of Adverse Events (CTCAE) version 4.0. This study defines severe neutropenia as grade 3-4 neutropenia. Tumor response was assessed by the Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. The primary objective was to recognize the risk factors of chemotherapy-induced severe neutropenia. The secondary objective was to determine outcomes in advanced-stage NSCLC.

Statistical analyses. Wilcoxon rank-sum tests were used to compare continuous data and data are reported as mean ± standard deviation (SD) or as median (range). Chi-square test or Fisher exact test were used to compare categorical data. To identify the factors associated with severe neutropenia, univariate and multivariate logistic regression were performed. Factors with a P-value < 0.10 in univariate analysis were evaluated as potential covariates in multivariate stepwise logistic regression analysis with backward selection. Survival curves were estimated using the Kaplan-Meier method. All reported P-values are two-tailed; a value below 0.05 was considered statistically significant. All analyses were performed using Stata version 15.1 (Stata Corp., College Station, TX, USA).

## Results

Patient Characteristic. Between July 2014 and January 2019, there were 259 patients with advanced-stage NSCLC who received chemotherapy; their toxicity information is available. The patient’s characteristics and pretreatment laboratory results are summarized in table1.

	Total (N=259)	Severe Neutropenia (N=37)	No severe neutropenia (N=222)	P-value
Age (years), mean (SD)	62.7 (9.4)	62.1 (8.3)	62.8 (9.6)	0.68
Female, n (%)	117 (45.2)	20 (54.1)	97 (43.7)	0.24
Smoking, n (%)	145 (56.2)	17 (46)	128 (57.9)	0.17
Smoking Pack-year,	31.5 (15.7)	31.6 (16.1)	30.8 (13.2)	0.84



mean (SD)				
Restriction of protein diet, n (%)	11 (4.3)	6 (16.2)	5 (2.3)	<0.001
Concomitant use herbal medicine, n (%)	4 (1.5)	2 (5.4)	2 (0.9)	0.1
Concomitant use anticoagulant, n (%)	12 (4.6)	1 (2.7)	11 (5)	0.55
BMI (kg/m <sup>2</sup> ), median (IQR)	18 (22.7-22.7)	17.9 (24-24)	18 (22.6-22.6)	0.17
Amount of weight loss (kg), median (IQR)	5 (3-8)	4.5 (3-6)	5 (4-8)	0.19
ECOG n (%)				0.002
ECOG0	51 (19.7)	15 (40.5%)	36 (16.2)	
ECOG1	146 (56.4)	19 (51.4)	127 (57.2)	
ECOG2	58 (22.4)	3 (8.1)	55 (24.8)	
ECOG3	4 (1.5)	-	4 (1.8)	
Baseline Laboratory				
Albumin (g/dl), median (IQR)	3.6 (3.1-4)	3.8 (3-4)	3.6 (3.1-4)	0.84
GFR (ml/min/1.73m <sup>2</sup> ), median (IQR)	76 (56-92)	60 (49-85)	78.3 (60-92)	0.006
Hemoglobin (g/dl), median (IQR)	11.8	11.5	11.8	0.43
	(10.5-12.8)	(10.1-12.4)	(10.6-12.8)	
WBC (mm <sup>3</sup> ), median (IQR)	9100	8410	9205	0.43
	(7360-11590)	(6990-10800)	(7450-11595)	
Neutrophil count (mm <sup>3</sup> ), median (IQR)	6117	5740	6165	0.31
	(4509-8250)	(4224-7640)	(4545-8475)	
Lymphocyte count (mm <sup>3</sup> ), median (IQR)	1714	1978	1708.5	0.12
	(1230-2349)	(1404-2508)	(1220-2335)	
Platelets (x10mm <sup>3</sup> ), median (IQR)	341	319	345.5	0.16
	(277-435)	(289-382)	(276.5-444)	
N/L Ratio, median (IQR)	3.5 (2.4-5.2)	2.9 (2.3-3.8)	3.5 (2.5-5.4)	0.08
Comorbid disease, n (%)	166 (64.1)	30 (81.1)	136 (61.3)	0.02
Renal disease, n (%)	59 (22.8)	15 (40.5)	44 (19.8)	0.01
Cardiovascular disease, n (%)	14 (5.4)	0 (0)	14 (6.3)	0.23
Diabetes mellitus, n (%)	25 (9.7)	2 (5.4)	23 (10.4)	0.55
COPD, n (%)	18 (7)	1 (2.7)	17 (7.7)	0.48
Liver disease, n (%)	4 (1.5)	1 (2.7)	3 (1.4)	0.54
Diagnosis				0.46
Newly diagnosis	255 (98.5)	36 (97.3)	219 (98.7)	
Recurrence disease	4 (1.5)	1 (2.7)	3 (1.4)	
TNM Stage				0.87
IIIB	26 (10)	22 (9.9)	4 (10.8)	
IV	233 (90)	200 (90.1)	33 (89.2)	
Histology n (%)				0.67
Adenocarcinoma	178 (69)	154 (69.7)	24 (64.9)	
SCCA	49 (19)	40 (18.1)	9 (24.3)	
Others	31 (12)	27 (12.2)	4 (10.8)	
EGFR Status n (%)				0.218

mutation	9 (3.5%)	3 (8.1%)	6 (2.7%)	
wide type	12 (4.6%)	1 (2.7%)	11 (5%)	
Number of organ metastasis				0.58
1	85 (32.8)	15 (40.5)	70 (31.5)	
2	80 (30.9)	8 (21.6)	72 (32.4)	
≥ 3	64 (24.7)	9 (24.3)	55 (24.8)	
Site of metastasis				
13 (5)	0 (0)	13 (5.9)	0.23	
Lung	139 (53.9)	20 (54.1)	119 (53.9)	0.98
liver	30 (11.6)	4 (10.8)	26 (11.7)	0.87
Bone/Soft tissue	51 (19.7)	6 (16.2)	45 (20.3)	0.57
Lymph node	47 (18.2)	6 (16.2)	41 (18.5)	0.74
Adrenal gland	30 (11.6)	2 (5.4)	28 (12.6)	0.21
Pleural	124 (47.9)	18 (48.7)	106 (47.8)	0.92

**Table 1. Baseline Characteristics.**

Abbreviation; BMI, Body Mass Index; GFR, Glomerular filtration rate; WBC, White Blood cell; NLR, Neutrophil/lymphocyte ratio; COPD, Chronic Obstructive Pulmonary disease; SCCA, Squamous Cell Carcinoma

There were 37 (14.28%) patients in the severe neutropenia group, 54.1% were female. The mean age was  $62.7 \pm 9.4$  years old. Of the 259 patients, 145 were smoking and the mean of cigarette smoking was  $31.5 \pm 15.7$  pack-year. Based on the 11 patients with a restricted protein diet, the likeliness of developing severe neutropenia was significant (16.2% vs 2.3%,  $P < 0.001$ ). Median baseline GFR was significantly lower in severe neutropenia than non-severe neutropenia (60 vs 78.3,  $p = 0.006$ ). The comorbid and renal disease were significantly more likely in severe neutropenia than in non-severe neutropenia (81.1% vs 61.1%,  $P < 0.02$  and 40.5% vs 19.8%,  $P < 0.01$  respectively). 255 patients (98.5%) were newly diagnosed with advanced-stage NSCLC. 178 patients have adenocarcinoma sub-type. The metastasis site was not different among groups.

246 (95%) patients received treatment with palliative chemotherapy; almost all chemotherapy regimens were platinum-based (Table 2).

	Total (N=259)	Severe Neutropenia (N=37)	No severe neutropenia (N=222)	P-value
Prior RT, n (%)	38 (14.7)	34 (15.3)	4 (10.8)	0.47
Total Dose RT (Gy) (N=41), mean (SD)	33.7 (13)	31.9 (11.7)	49.8 (15.5)	0.01
Treatment, n(%)				0.16
Palliative CMT	246 (95)	34 (91.9)	212 (95.5)	
Concurrent Chemoradiation	2 (0.8)	1 (2.7)	1 (0.5)	
Sequential CMT then RT	9 (3.5)	1 (2.7)	8 (3.6)	
Sequential RT then CMT	2 (0.8)	1 (2.7)	1 (0.5)	
Regimen Chemotherapy				<0.001
Single-agent platinum	36 (13.9)	0 (0)	36 (16.2)	
Platinum/Gemcitabine	44 (17)	20 (54.1)	24 (10.8)	
Platinum/Taxane	176 (68)	16 (43.2)	160 (72.1)	
Cycle, median (IQR)	4 (3-6)	6 (4-6)	4 (3-6)	0.04
Duration of treatment,	77 (49-110)	93 (67-119)	73.5 (43-106)	0.006

Mean (days)				
Dose reduction				<0.001
1 level, n (%)	84 (32.43)	27 (73)	57 (25.7)	
2 level, n (%)	2 (0.007)	0 (0)	2 (0.9)	
Dose interrupt, n (%)	77 (29.72)	29 (78.4)	48 (21.7)	<0.001
Infection	23 (11.9)	2 (5.4)	21 (9.5)	0.55

**Table 2. Treatment and Side Effects.**

Abbreviation; CMT, Chemotherapy; RT, radiation

The highest incidence of severe neutropenia (54.1%) was found in patients with a platinum/gemcitabine regimen. There was a significant difference in the median of cycle chemotherapy and duration of treatment among groups (6 vs 4 cycles; P=0.004 and 93 vs 73.5 days respectively). 38 (14.7%) patients received radiation before systemic treatment. The mean total dose radiation was 31.9 ± 11.7 and 49.8 ± 15.5 Gy in severe neutropenia and non-severe neutropenia with statistically significant (P=0.01). Febrile neutropenia was found in 1.2% (3 patients). The infection rate was not different among groups (P=0.55).

Univariate analysis for severe neutropenia revealed that restriction of protein diet (OR 8.4; 95% CI 2.42-29.17; P=0.001), concomitant use herbal medicine (OR 6.29; 95% CI 0.86-46.08; P=0.007), high BMI (BMI ≥ 25) (OR 2.79; 95% CI 1.12-6.91; P=0.03), GFR < 60 mL/min/1.73m<sup>2</sup> (OR 2.95; 95% CI 1.44-6.02; P=0.003), comorbid disease (OR 2.71; 95% CI 1.14-6.44; P=0.02), renal disease (OR 2.76; 95% CI 1.32-5.75; P=0.01), number cycles > 4 (OR 4.59; 95% CI 1.36-15.48; P=0.01), Platinum/ Gemcitabine (OR 8.33; 95% CI 3.8-18.27; P=0.001) were significantly associated with CISN. Multivariate stepwise logistic regression analysis with backward selection revealed that restriction of protein diet (OR 9.54; 95% CI 2.44-37.24; P=0.001), concomitant use herbal medicine (OR 8.66; 95% CI 1.04-72.07; P=0.045), high BMI (OR 3.1; 95% CI 1.07-8.99; P=0.04), renal disease (OR 3.9; 95% CI 1.7-8.91; P=0.001), number of cycle chemotherapy > 4 (OR 3.97; 95% CI 1.11-14.18; P=0.03) were significant predictors of severe neutropenia (Table 3).

Factors	Univariate		Multivariate	
	OR (95% CI)	P-value	OR (95% CI)	P-Value
Age > 60	1.04 (0.5-2.15)	0.92		
Female	1.52 (0.75-3.05)	0.24		
Smoking	0.62 (0.31-1.24)	0.18		
Restriction of protein diet:	8.4 (2.42-29.17)	0.001	9.54 (2.44-37.24)	0.001
Concomitant use of herbal medicine	6.29 (0.86-46.08)	0.07	8.66 (1.04-72.07)	0.045
Concomitant use anticoagulant	0.53 (0.07-4.25)	0.55		
BMI ≥ 25 kg/m <sup>2</sup>	2.79 (1.12-6.91)	0.03	3.1 (1.07-8.99)	0.04
Amount of weight loss (kg)	0.93 (0.84-1.02)	0.13		
Albumin (mg/dL)	1.12 (0.62-2.03)	0.7		
GFR < 60 mL/min/1.73m <sup>2</sup>	2.95 (1.44-6.02)	0.003		
Hemoglobin (g/dL)	0.93 (0.76-1.14)	0.48		
WBC (x10 <sup>3</sup> /mm <sup>3</sup> )	0.99 (0.98-1)	0.6		
Neutrophil Count (x10 <sup>3</sup> /mm <sup>3</sup> )	0.99 (0.98-1)	0.85		
Lymphocyte count (x10 <sup>3</sup> /mm <sup>3</sup> )	0.99 (0.98-1)	0.17		

platelets count (x10 <sup>3</sup> /mm <sup>3</sup> )	0.99 (0.98-1)	0.11		
N/L Ratio > 2.5	1.42 (0.67-3.02)	0.36		
Comorbid disease	2.71 (1.14-6.44)	0.02		
Renal disease	2.76 (1.32-5.75)	0.01	3.9 (1.7-8.91)	0.001
Platinum/Gem	8.33 (3.8-18.27)	<0.001		
Platinum/taxane	1			
Number of Cycle > 4	4.59 (1.36-15.48)	0.01	3.97 (1.11-14.18)	0.03
Radiation	0.67 (0.22-2.01)	0.48		

**Table 3. Univariate and Multivariate Analysis for Severe Neutropenia.**

The Data cutoff was June 30, 2021. At this time the median follow-up period was 2 years. 244 patients had progression events and 70 patients passed away. The response rate was similar among groups (Table 4).

	Total (N=244)	Severe Neutropenia (N=37)	No severe neutropenia (N=207)	P-value
Response treatment				0.2
Partial response	61 (25.5)	7 (18.9)	54 (26.7)	
Stable disease	116 (48.5)	23 (62.2)	93 (46)	
Progressive disease	62 (25.9)	7 (18.9)	55 (27.2)	
6 months PFS (%)	69.5 (63.2-75)	81 (64.2-90.5)	67.4 (60.4-73.4)	0.04
1 year OS (%)	54.3 (42-65.1)	53.9 (24.8-76)	75.4 (62.1-84.7)	0.35
2 years OS (%)	40 (28.6-51.2)	38.5 (14.1-62.8)	40.4 (27.7-52.7)	0.95

**Table 4. Treatment Outcomes.**

Abbreviation; PFS, Progression-Free Survival; OS, Overall Survival.

The median progression-free survival (mPFS) in severe neutropenia and non-severe neutropenia were 9.6 (6.8-15.6) and 8.2 (4.9-14.8) months respectively (P=0.32). No difference in overall survival (median OS 13.8 vs 16.7 months, P=0.79) (Figure 1 and 2).

**Figure 1. Progression-free Survival.**

**Figure 2. Overall Survival.**

## Discussion

The present study examined the risk factors associated with chemotherapy-induced severe neutropenia in patients with advanced-stage NSCLC. The result revealed that low baseline GFR, comorbid disease, platinum/gemcitabine regimen, and long duration of exposure to chemotherapy were associated with severe neutropenia. Multivariate logistic regression analysis found that restriction of protein diet, concomitant chemotherapy use of herbal medicine, BMI  $\geq$  25 kg/m<sup>2</sup>, renal disease, and more than 4 cycles of chemotherapy were significant risk factors for CISN.

Dietary restriction-induced sarcopenia and increased risk of cachexia. Therefore, the dietary restriction may not be suitable for patients undergoing cancer treatment. As Hastreiter (2020) reported that protein malnutrition decreased hematopoietic stem cells and promote cell cycle

arrest [21]. Few studies of protein-restricted diet in cancer treatment were identified. One study was a randomized crossover trial in 27 patients treated with irinotecan found that a protein-restricted diet did not demonstrate the difference in WBC and neutrophil count after irinotecan treatment. Protein-restricted diet and toxicity during cancer treatment and oncological outcome require further exploration. However, the European Society for Clinical Nutrition and Metabolism (ESPEN) guideline recommended that protein intake should be above 1 g/kg/day and if possible, up to 1.5 g/kg/day in cancer patients [22].

Nowadays, Herbs have an increasingly significant role in the treatment of cancer with conventional treatment. Based on Naja et al (2017), the incidence of herbal medicine usage in cancer patients were 22-54% [23]; however, the prevalence in this study was 1.5%. This may be due to the doctors' and teams' advice to refrain from using herbs during treatment, or the patients' history was hidden. Many studies explored the efficacy and safety to use herbal medicine with chemotherapy for treatment of cancer, especially in China. Chinese herbal medicine (CHM) alongside chemotherapy showed benefits in reduced non-hematologic toxicity [24,25] and does not show an increased risk of neutropenia in breast cancer [26]. Currently, a meta-analysis evaluated the efficacy of traditional herbal medicine (THM) combined with first-line platinum-based chemotherapy (PBCT) for the treatment of advanced NSCLC revealed that THM combined with PBCT lower the incidence of thrombocytopenia but does not affect neutropenia [27]. A systematic review of fifteen Chinese trials involving 862 participants found that CHM combined with chemotherapy reduces the risk of myelosuppression in stages III-IV NSCLC (RR 0.42, 95% CI 0.22-0.82,  $p=0.01$ ) compared to chemotherapy alone [28]. However, all trials possessed a noticeable risk of bias, with omissions of potential adverse effects of CHM. The results of previous studies were inconsistent with the findings in this study. This may be due to the different types of herbs used in Thailand and their pharmacogenetic effects, as compared to medicinal herbs researched in literature. The efficacy and safety to use of herbal products as complementary or alternative medicine need to be further explored. The larger sample size of high-quality randomized control trials (RCTs) are necessary to reduce study heterogeneity. In Chotipanich et al. (2019) [29], complementary and alternative medicine use in cancer patients was associated with delayed time to receive standard treatment. Therefore, fixation on complementary and alternative medicine use can be a serious impediment to standard healthcare.

Based on this study,  $BMI \geq 25 \text{ mg/m}^2$  is a risk factor for severe neutropenia. Bodyweight affects chemotherapy dose calculation; obese people will get a high dose of the drug, which may result in a higher occurrence of side effects. Kashiwabara et al. (2013) [30] compared the onset of hematologic toxicity in patients with chemotherapy treatment for lung cancer who were categorized into  $BMI < 25 \text{ mg/m}^2$  and  $\geq 25 \text{ mg/m}^2$ . They found that grade 4 neutropenia is significantly more common among patients with  $BMI \geq 25 \text{ mg/m}^2$  than  $BMI < 25 \text{ mg/m}^2$  group (43% vs 24%,  $P<0.005$ ); patients with  $BMI \geq 25 \text{ mg/m}^2$  also required G-CSF and a reduction in carboplatin dose. Fernando Gutierrez et al (2016) [31] categorize patients with hematologic toxicity in gynecologic malignancy, who received full-dose carboplatin, into overweight ( $BMI \geq 27 \text{ mg/m}^2$ ) and normal weight ( $BMI < 27 \text{ mg/m}^2$ ). The overweight group showed a higher incidence of grade III-IV hematologic toxicity, albeit without statistical significance. Similarly, Furlanetto et al (2016) [32] showed that obese breast cancer patients were more likely to have hematologic side effects but no difference in grade III- IV neutropenia. Other studies revealed obesity did not increase the risk of grade III-IV neutropenia. Therefore, it was unnecessary to use uncapped chemotherapy doses by body size in patients with solid tumors [33-35]. Recently, the ASCO guideline provided evidence that myelosuppression is the same in obese and non-obese patients [36]. However, the ASCO guidelines based its research on mostly Caucasian and African-American cancer patients pool. Future research should focus on total body drug distribution and the impact of obesity on side effects of chemotherapy, specifically in the Asian population.

Comorbid diseases and renal diseases were associated with CISN. However, only renal diseases were strong predictors of severe neutropenia, which is consistent with prior studies [37]. Renal diseases impair neutrophil function [38] resulting in an increased risk of CISN and neutropenic

complications. Patients receiving more than 4 cycles of chemotherapy is a risk factor for CISN which is consistent with past studies [27]. The data may indicate the false association between the number cycle of chemotherapy and severe neutropenia; patients who received more cycles of treatment had a greater accumulation of chemotherapy drugs, resulting in a higher incidence of severe neutropenia. There was no difference in response rate, progression-free survival and overall survival between severe and non-severe neutropenia consistent with prior study [39]. Gargiulo et al (2021) [40] report the pooled analysis of 6 RCTs reveals that CISN was a predictive factor of prognosis in lung cancer (hazard ratio of death 0.71; 95%CI: 0.53-0.95, p=0.048. However, it was an unclear association between the severity of CIN and a prognostic factor. The response of cancer cells to chemotherapy depends on the sufficiency of active drugs, the sensitivity of cancer to chemotherapy, cancer cells' resistance to the drug, genetic predisposition, and pharmacokinetics of chemotherapy. There were many factors that affected cancer mortality. This suggested different performance status, immune status, tumor burden, oncogenic mutations, and subsequent treatment may affect the prognostic value of CISN.

In conclusion, our data indicate that protein-restricted diet, concomitant use of herbal medicine, BMI  $\geq 25$  kg/m<sup>2</sup>, renal disease, and more than 4 cycles of chemotherapy are significant risk factors for CISN in advanced-stage NSCLC. Therefore, patients with these risk factors should be more carefully monitored or adjusted dose of chemotherapy. However, the limitation of this study was the retrospective design, resulting in some relevant information on medical records not being recorded. Further investigation will develop and assess the accuracy of predictive models that clinicians can use to assess a patient's risk for the development of severe neutropenia and neutropenic complications during the course of chemotherapy.

#### *Conflict of interest*

The authors declare that no conflict of interests was present during the making of the study

#### *Ethical Declaration*

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors

#### *Ethics Approval*

This study has been approved by The Committee of The Medical Research Ethics of Sawanpracharak Hospital with reference no. 44/2564

#### *Author Contribution Statement*

S.N - contributed to the conception, design, data analysis, and manuscript writing.

## **References**

## **References**

1. Sung Hyuna, Ferlay Jacques, Siegel Rebecca L., Laversanne Mathieu, Soerjomataram Isabelle, Jemal Ahmedin, Bray Freddie. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: a*



- cancer journal for clinicians*. 2021; 71(3)[DOI](#)
2. Herbst Roy S., Heymach John V., Lippman Scott M.. Lung cancer. *The New England Journal of Medicine*. 2008; 359(13)[DOI](#)
  3. Riess JW, Wakelee HA. Metastatic non-small cell lung cancer management: novel targets and recent clinical advances. *Clinical advances in hematology & oncology : H&O*. 2012; 10(4)
  4. Reck Martin, Heigener David F., Mok Tony, Soria Jean-Charles, Rabe Klaus F.. Management of non-small-cell lung cancer: recent developments. *Lancet (London, England)*. 2013; 382(9893)[DOI](#)
  5. Johnson DH, Schiller JH, Bunn PA. Recent clinical advances in lung cancer management. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2014; 32(10)[DOI](#)
  6. Schiller Joan H., Harrington David, Belani Chandra P., Langer Corey, Sandler Alan, Krook James, Zhu Junming, Johnson David H.. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *The New England Journal of Medicine*. 2002; 346(2)[DOI](#)
  7. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *The New England journal of medicine*. 2006; 355(24)[DOI](#)
  8. Mok Tony S., Wu Yi-Long, Thongprasert Sumitra, Yang Chih-Hsin, Chu Da-Tong, Saijo Nagahiro, Sunpaweravong Patrapim, Han Baohui, Margono Benjamin, Ichinose Yukito, Nishiwaki Yutaka, Ohe Yuichiro, Yang Jin-Ji, Chewaskulyong Busyamas, Jiang Haiyi, Duffield Emma L., Watkins Claire L., Armour Alison A., Fukuoka Masahiro. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *The New England Journal of Medicine*. 2009; 361(10)[DOI](#)
  9. Crawford Jeffrey, Dale David C., Lyman Gary H.. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. *Cancer*. 2004; 100(2)[DOI](#)
  10. Kwak L. W., Halpern J., Olshen R. A., Horning S. J.. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 1990; 8(6)[DOI](#)
  11. Ahn Shin, Lee Yoon-Seon, Chun Yun-Hee, Kwon In-Ho, Kim Won, Lim Kyung Soo, Kim Tae Won, Lee Kyoo-Hyung. Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia. *Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer*. 2011; 19(8)[DOI](#)
  12. Chindaprasirt Jarin, Wanitpongpun Chinadol, Limpawattana Panita, Thepsuthammarat Kaewjai, Sripakdee Warunsuda, Sookprasert Aumkhae, Wirasorn Kosin. Mortality, length of stay, and cost associated with hospitalized adult cancer patients with febrile neutropenia. *Asian Pacific journal of cancer prevention: APJCP*. 2013; 14(2)[DOI](#)
  13. Dees E. C., O'Reilly S., Goodman S. N., Sartorius S., Levine M. A., Jones R. J., Grochow L. B., Donehower R. C., Fetting J. H.. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. *Cancer Investigation*. 2000; 18(6)[DOI](#)
  14. Voog E., Bienvu J., Warzocha K., Moullet I., Dumontet C., Thieblemont C., Monneret G., Gutowski M. C., Coiffier B., Salles G.. Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand-receptor system. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 2000; 18(2)[DOI](#)
  15. Morrison VA, Picozzi V, Scott S, Pohlman B, Dickman E, Lee M, Lawless G, Kerr R, Caggiano V, Delgado D, Fridman M, Ford J, Carter WB. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. *Clinical lymphoma*. 2001; 2(1)[DOI](#)
  16. Wilson-Royalty M, Lawless G, Palmer C, Brown R. Predictors for chemotherapy-related severe or febrile neutropenia: a review of the clinical literature. *J Oncol Pharm Pract*. 2002;

- 7:141-147.
17. Morrison VA, Caggiano V, Fridman N, Delgado DJ. A model to predict chemotherapy-related severe or febrile neutropenia in cycle one among breast cancer and lymphoma patients. *J Clin Oncol*. 2004; 23:742.
  18. Jenkins P., Freeman S.. Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer. *Annals of Oncology: Official Journal of the European Society for Medical Oncology*. 2009; 20(1)[DOI](#)
  19. Schwenkglenks Matthias, Pettengell Ruth, Jackisch Christian, Paridaens Robert, Constenla Manuel, Bosly André, Szucs Thomas D., Leonard Robert. Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study. *Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer*. 2011; 19(4)[DOI](#)
  20. Bozcuk H, Yıldız M, Artaç M, Kocer M, Kaya C, Ulukal E, Ay S, Kılıç MP, Şimşek EH, Kılıçkaya P, Uçar S, Coskun HS, Savas B. A prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter study. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*. 2015; 23(6)[DOI](#)
  21. Hastreiter Araceli Aparecida, Galvão Dos Santos Guilherme, Cavalcante Santos Ed Wilson, Makiyama Edson Naoto, Borelli Primavera, Fock Ricardo Ambrósio. Protein malnutrition impairs bone marrow endothelial cells affecting hematopoiesis. *Clinical Nutrition (Edinburgh, Scotland)*. 2020; 39(5)[DOI](#)
  22. Muscaritoli Maurizio, Arends Jann, Bachmann Patrick, Baracos Vickie, Barthelemy Nicole, Bertz Hartmut, Bozzetti Federico, Hütterer Elisabeth, Isenring Elizabeth, Kaasa Stein, Krznaric Zeljko, Laird Barry, Larsson Maria, Laviano Alessandro, Mühlebach Stefan, Oldervoll Line, Ravasco Paula, Solheim Tora S., Strasser Florian, Schueren Marian, Preiser Jean-Charles, Bischoff Stephan C.. ESPEN practical guideline: Clinical Nutrition in cancer. *Clinical Nutrition (Edinburgh, Scotland)*. 2021; 40(5)[DOI](#)
  23. Naja Farah, Anouti Bilal, Shatila Hibeh, Akel Reem, Haibe Yolla, Tfayli Arafat. Prevalence and Correlates of Complementary and Alternative Medicine Use among Patients with Lung Cancer: A Cross-Sectional Study in Beirut, Lebanon. *Evidence-based Complementary and Alternative Medicine : eCAM*. 2017; 2017[DOI](#)
  24. Mok T. S. K., Yeo W., Johnson P. J., Hui P., Ho W. M., Lam K. C., Xu M., Chak K., Chan A., Wong H., Mo F., Zee B.. A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. *Annals of Oncology: Official Journal of the European Society for Medical Oncology*. 2007; 18(4)[DOI](#)
  25. Ben-Arye Eran, Samuels Noah, Goldstein Lee Hilary, Mutafoglu Kamer, Omran Suha, Schiff Elad, Charalambous Haris, Dweikat Tahani, Ghrayeb Ibtisam, Bar-Sela Gil, Turker Ibrahim, Hassan Azza, Hassan Esmat, Saad Bashar, Nimri Omar, Kebudi Rejin, Silbermann Michael. Potential risks associated with traditional herbal medicine use in cancer care: A study of Middle Eastern oncology health care professionals. *Cancer*. 2016; 122(4)[DOI](#)
  26. Liew Ai Ch'i, Peh Kok-Khiang, Tan Boon Seang, Zhao Wei, Tangiisuran Balamurugan. Evaluation of chemotherapy-induced toxicity and health-related quality of life amongst early-stage breast cancer patients receiving Chinese herbal medicine in Malaysia. *Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer*. 2019; 27(12)[DOI](#)
  27. Jin Hayun, Park Su Bin, Yoon Jee-Hyun, Lee Jee Young, Kim Eun Hye, Yoon Seong Woo. Traditional herbal medicine combined with first-line platinum-based chemotherapy for advanced non-small-cell lung cancer: A PRISMA-compliant systematic review and meta-analysis. *Medicine*. 2021; 100(37)[DOI](#)
  28. Chen Sisi, Flower Andrew, Ritchie Andrew, Liu Jianping, Molassiotis Alex, Yu He, Lewith George. Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: A systematic review. *Lung Cancer (Amsterdam, Netherlands)*. 2010; 68(2)[DOI](#)

29. Chotipanich A, Sooksrisawat C, Jittiworapan B. Association between complementary and alternative medicine use and prolonged time to conventional treatment among Thai cancer patients in a tertiary-care hospital. *PeerJ*. 2019; 7<sup>DOI</sup>
30. Kashiwabara Kosuke, Yamane Hiromi, Tanaka Hideyuki. Toxicity and prognosis in overweight and obese women with lung cancer receiving carboplatin-paclitaxel doublet chemotherapy. *Cancer Investigation*. 2013; 31(4)<sup>DOI</sup>
31. Gutierrez Fernando, Gonzalez-de-la-Fuente Guillermo Antonio, Nazco Gloria Julia, Oramas Juana, Batista Norberto. Hematological toxicity of carboplatin for gynecological cancer according to body mass index. *European Journal of Clinical Pharmacology*. 2016; 72(9)<sup>DOI</sup>
32. Furlanetto J., Eiermann W., Marmé F., Reimer T., Reinisch M., Schmatloch S., Stickeler E., Thomssen C., Untch M., Denkert C., Minckwitz G., Lederer B., Nekljudova V., Weber K., Loibl S., Möbus V.. Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study. *Annals of Oncology: Official Journal of the European Society for Medical Oncology*. 2016; 27(11)<sup>DOI</sup>
33. Kamimura Kensuke, Matsumoto Yoshifumi, Zhou Qiliang, Moriyama Masato, Saijo Yasuo. Myelosuppression by chemotherapy in obese patients with gynecological cancers. *Cancer Chemotherapy and Pharmacology*. 2016; 78(3)<sup>DOI</sup>
34. Lote H, Sharp A, Redana S, Papadimitraki E, Capelan M, Ring A. Febrile Neutropenia Rates According to Body Mass Index and Dose Capping in Women Receiving Chemotherapy for Early Breast Cancer. *Clinical oncology (Royal College of Radiologists (Great Britain))*. 2016; 28(9)<sup>DOI</sup>
35. Ando Yosuke, Hayashi Takahiro, Shiouchi Hideyo, Tanaka Chihiro, Ito Kaori, Nishibe Seira, Miyata Nanaho, Horiba Ruri, Yanagi Hisano, Fujii Takuma, Kawada Kenji, Ikeda Yoshiaki, Yamada Shigeki. Effect of Obesity on Hematotoxicity Induced by Carboplatin and Paclitaxel Combination Therapy in Patients with Gynecological Cancer. *Biological & Pharmaceutical Bulletin*. 2020; 43(4)<sup>DOI</sup>
36. Griggs Jennifer J., Bohlke Kari, Balaban Edward P., Dignam James J., Hall Evan T., Harvey R. Donald, Hecht Diane P., Klute Kelsey A., Morrison Vicki A., Pini T. May, Rosner Gary L., Runowicz Carolyn D., Shayne Michelle, Sparreboom Alex, Turner Sophia, Zarwan Corrine, Lyman Gary H.. Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 2021; 39(18)<sup>DOI</sup>
37. Chao C, Page JH, Yang SJ, Rodriguez R, Huynh J, Chia VM. History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis. *Annals of oncology : official journal of the European Society for Medical Oncology*. 2014; 25(9)<sup>DOI</sup>
38. Heinzelmann M., Mercer-Jones M. A., Passmore J. C.. Neutrophils and renal failure. *American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation*. 1999; 34(2)<sup>DOI</sup>
39. Kishida Y., Kawahara M., Teramukai S., Kubota K., Komuta K., Minato K., Mio T., Fujita Y., Yonei T., Nakano K., Tsuboi M., Shibata K., Atagi S., Kawaguchi T., Furuse K., Fukushima M.. Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03. *British Journal of Cancer*. 2009; 101(9)<sup>DOI</sup>
40. Gargiulo Piera, Arenare Laura, Gridelli Cesare, Morabito Alessandro, Ciardiello Fortunato, Gebbia Vittorio, Maione Paolo, Spagnuolo Alessia, Palumbo Giuliano, Esposito Giovanna, Della Corte Carminia Maria, Morgillo Floriana, Mancuso Gianfranco, Di Liello Raimondo, Gravina Adriano, Schettino Clorinda, Di Maio Massimo, Gallo Ciro, Perrone Francesco, Piccirillo Maria Carmela. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials. *BMC Cancer*. 2021; 21(1)<sup>DOI</sup>